// App-Quantinova.ai

34 : Sustained Response Outcomes from a Phase IIA, Randomized, Double-blind, Placebo-controlled Study of LY2951742, a Monoclonal Antibody to Calcitonin Gene-related Peptide for the Prevention of Migraine: A Post-hoc Analysis

Researchers

Presenter

  • David Dodick

Principal Investigators

  • Peter Goadsby

  • Vladimir Skjlarevski

  • Margaret Ferguson

  • Tina Oakes

  • Yoko Tanaka

  • Xiao Ni

  • Qi Zhang

  • Michael Due

  • James Martinez

  • Matthew Sexson

Medical Centers

  • Kings College London, London, UK

  • Eli Lilly and Company, Indianapolis, IN

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Migraine

Biomarkers

  • Calcitonin

Drug/Treatment

  • Calcitonin

  • LY2951742

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT01625988

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved